Biotechnology

A new partnership between a Chinese biotech and a Brazilian public institute aims to slash the $500k cost of CAR-T therapy, making it accessible to all.

A new study shows the feasibility of a single device for glucose monitoring and insulin delivery, aiming to simplify life for millions with diabetes.

With a massive $54M Series A, Vivatides Therapeutics aims to solve RNA's biggest delivery problem, unlocking new treatments for a host of chronic diseases.

At analytica 2026, Haier Biomedical unveiled its 'In Europe, For Europe' strategy, challenging market leaders with integrated solutions and local roots.

A new partnership combines local infrastructure with global expertise, aiming to streamline development for startups and solidify Singapore's biotech leadership.

Ditching the static model, CleanSpace is building a full-scale, operational pharmaceutical factory on the tradeshow floor, a move set to transform B2B marketing.

Five new clinical trials in Chicago repurpose existing drugs for PTSD, cancer, and more, offering a faster, cheaper path to treating unsolved diseases.

Powered Research will unveil an AI that speeds drug testing for retinal diseases and key findings on animal models, aiming to transform preclinical studies.

In a significant move, 35 workers at a key biopharmaceutical firm supporting the CDC and FDA have unionized, highlighting new frontiers for organized labor.

With late-stage trials for two common eye conditions affecting millions, Cloudbreak Pharma is advancing novel drops where no approved drugs exist.

Positive Phase 1b data for two novel drugs suggests a long-acting, once-monthly oral therapy for recurrent genital herpes may be on the horizon.

As drug-resistant superbugs threaten modern medicine, a novel liquid therapeutic from Seres Therapeutics offers a lifeline for the most vulnerable patients.

Behavior Labs launches a new platform to close the life sciences' 'ground truth gap,' replacing slow quarterly reviews with continuous, daily intelligence.

With Christoph Korpus at the helm, Byondis signals a strategic shift to accelerate its innovative cancer therapies through new partnerships and commercialization.

With Nuvaxovid set for a 2026 rollout, Sanofi aims to address vaccine hesitancy and expand choices as Canada continues to battle the virus.

China's Gan & Lee partners with JW Pharmaceutical to launch its novel bi-weekly GLP-1 drug, Bofanglutide, into the competitive South Korean market.

With a personal family connection to type 1 diabetes and a £100M war chest, Anastasia Bukhman joins the T1D Fund's board to speed up research.

A new non-invasive therapy using ultrasound to activate a cancer-targeting drug enters a crucial Phase 2b trial, offering new hope for glioblastoma patients.

New Medicare billing codes for the biosimilar Tyenne are now in effect, simplifying reimbursement and aiming to improve access for severe COVID-19 patients.

With its European trial launch, Kainova's DT-7012 aims to disarm cancer's bodyguards, offering new hope for patients with advanced solid tumors.